Pipeline

Main Pipeline Development Status (as of April 2022)

*You can scroll horizontally

Surgery
Product Area Non-clinical
study
Clinical
study
Application Approval Launch
Hemostat
(Purastat)
CE marking countries
Japan
US
Started production
Prevention of delayed bleeding
(Purastat)
CE marking countries
US
Started production
Japan
Next-generation hemostat
(TDM-623)
CE marking countries
Anti-adhesion material
(Purasinus)
US
Mucous membrane
Lifting-up solution
(TDM-644)
Japan
Preparing for insurance coverage
Tissue regeneration
Product Area Non-clinical
study
Clinical
study
Application Approval Launch
Wound healing
Material
(PuraDerm)
US
Preparing for cosmetic surgery
Rectal mucositis US
CE marking countries
Japan
Inflammatory bowel disease CE marking countries
Japan
US
DDS
Product Area Non-clinical
study
Clinical
study
Application Approval Launch
Triple negative breast cancer
(TDM-812)
Japan
Malignant pleural mesothelioma
(MIRX002)
Japan
Under development by licensee